Axalta Posts Record Q2 Adjusted EBITDA of $305M Ahead of Merger Vote
AXTA sits 39% above its 52-week low of $24.937.
Summary
Axalta reported Q2 2026 results with record Adjusted EBITDA of $305 million and Adjusted Diluted EPS of $0.72, while merger costs weighed on reported net income. The earnings release comes one week before the shareholder vote on the AkzoNobel merger of equals.
Key Events · Earnings and Guidance · AXTA
-
Record Adjusted EBITDA
Adjusted EBITDA rose 5% YoY to a quarterly record of $305 million, with margin expanding 30 bps to 22.7%.
-
Adjusted EPS Hits Record
Adjusted Diluted EPS of $0.72 increased 13% YoY, while reported diluted EPS fell to $0.41 due to $31 million in merger-related costs.
-
Merger Vote on August 5
CEO Chris Villavarayan highlighted the upcoming Special General Meeting to approve the AkzoNobel merger, calling it a compelling combination with significant value creation.
-
Free Cash Flow Improves
Free cash flow reached $107 million, up $6 million YoY, despite merger-related headwinds, supported by improved working capital and lower interest payments.
Analysis · AXTA · Industrial Applications And Services
Axalta delivered a record quarter for Adjusted EBITDA and Adjusted Diluted EPS, driven by cost controls and lower interest expense. Reported net income fell due to $31 million in merger-related costs tied to the AkzoNobel deal. The strong underlying performance arrives just ahead of the August 5 shareholder vote on the merger, reinforcing management's case that the combination creates value. Free cash flow also improved, providing financial flexibility as the transaction nears completion.
At the time of this filing, AXTA was trading at $34.73 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $24.94 to $35.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.